Barinthus Biotherapeutics (BRNS) Proxy Filing summary

Executive summary

• The annual general meeting is scheduled for June 10, 2025, with key proposals including director re-elections, auditor appointments, and approval of compensation policies.

• Shareholders can vote in person or by proxy, with detailed instructions for ordinary and ADS holders.

• The Board unanimously recommends voting in favor of all proposals, emphasizing alignment with company success.

Voting matters and shareholder proposals

• Eight ordinary resolutions will be voted on, including re-election of two directors, auditor appointments, remuneration policy, and advisory approval of the compensation report.

• Shareholders may submit proposals for the 2026 AGM, with deadlines and requirements outlined.

• Shareholder rights include the ability to call a general meeting with 5% of paid-up shares.

Board of directors and corporate governance

• The Board consists of seven members divided into three classes, with staggered three-year terms.

• Board committees include Audit, Compensation, and Nominating and Corporate Governance, all with independent members.

• The Board separates the roles of CEO and Chairman to ensure independent oversight.

• Board and committee meetings were well-attended in 2024, and director qualifications emphasize industry experience and independence.